| Symbol | IMMB |
|---|---|
| Name | IMMUNOTECH LABORATORIES, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 91016 United States CA 120 W. Pomona Avenue |
| Telephone | 626-538-4779 |
| Fax | — |
| — | |
| Website | http://www.immunotechlab.com |
| Incorporation | US |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | UNAUDITED |
| Reporting Status | Dark: Alternative Reporting Standard |
| CIK | 0001137117 |
| Description | Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Immunotechs flagship compound ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. >IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective. Additional info from OTC: |
Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: IMMUNOTECH LABS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: IMMUNOTECH LABS INC.
Read more